214 results on '"Willems, Bernard"'
Search Results
2. Potential availability of metals in anaerobic mono- and co-digestion of pig manure and maize
3. Evolving trends in liver transplantation eligibility: A shift toward inclusivity for older adults at a Canadian Transplant Center.
4. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
5. Corrigendum to “Potential availability of metals in anaerobic mono- and co-digestion of pig manure and maize” [Bioresour. Technol. (2024) 130818/402]
6. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
7. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant
8. Hepatic evaluation of patients with telomeropathies
9. Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures
10. Maximizing nutrient recycling from digestate for production of protein-rich microalgae for animal feed application
11. The power of QDDs (extended abstract)
12. A real-world experience of SARS-CoV-2 infection in a tertiary referral centre of Montréal: Unexpected low prevalence and low mortality
13. Sequence Analysis of the 5′ Noncoding Region Reveals the Existence of Multiple Hepatitis C Virus Genotypes in Quebec, Canada
14. Cefotaxime, Desacetyl-Cefotaxime, and Bactericidal Activity in Spontaneous Bacterial Peritonitis
15. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
16. Assessment of Fatigue in Patients with Chronic Hepatitis C Using the Fatigue Impact Scale
17. Stability of Thermophilic Pig Manure Mono-digestion: Effect of Thermal Pre-treatment and Separation
18. Erratum to: IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test
19. Primary cultures of human hepatocytes isolated from hepatitis C virus-infected cirrhotic livers as a model to study hepatitis C infection
20. 265 Early but not late interferon alpha therapy against hepatitis C rescues polyfunctional CD4+ and CD8+ memory T cells
21. 165 Higher efficacy of Peg-IFN-α2 ribavirin combined therapy in HCV-infected patients with functional myeloid dendritic cells (MDC)
22. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies
23. Effect of separation and thermal pre-treatment on process stability of pig manure mono-digestion
24. Reuse of liver graft from a brain dead recipient
25. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
26. Surgical treatment of severe postshunt hepatic encephalopathy
27. The power of QDDs (extended abstract)
28. StenoseVCI-Suppmat – Supplemental material for Acute Kidney Injury Due to Inferior Vena Cava Stenosis After Liver Transplantation: A Case Report About the Importance of Hepatic Vein Doppler Ultrasound and Clinical Assessment
29. Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection
30. Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
31. Inoculum selection influences the biochemical methane potential of agro-industrial substrates
32. Spontaneously reversible extensive portal vein thrombosis after gallbladder puncture during transjugular liver biopsy
33. Biological and clinicopathological features associated with hepatitis C virus type 5 infections
34. IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies
35. IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis
36. Acute Kidney Injury Due to Inferior Vena Cava Stenosis After Liver Transplantation: A Case Report About the Importance of Hepatic Vein Doppler Ultrasound and Clinical Assessment
37. Use of the 5' Noncoding Region for Genotyping Hepatitis C Virus
38. Ro 15–1788 Kinetics are Markedly Impaired in Cirrhotic Patients.
39. P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies
40. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
41. Th17 Cytokines Drive Liver Fibrosis Progression by Regulating TGF-β Signaling through Activation of MAPKs
42. No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in DAA-Naïve Patients: An Integrated Resistance Analysis of the POLARIS-2 and POLARIS-3 Studies
43. SOF/VEL/VOX Results in High SVR12 Rates when Administered for 12 Weeks in Daa-Experienced Patients or for 8 Weeks in Daa-Naïve Patients: An Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 Studies
44. Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR)
45. The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in > 1,000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: An Integrated Analysis
46. Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies
47. (Bio)-enzymatic additives to boost anaerobic digestion
48. Sa1497 - The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in > 1,000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: An Integrated Analysis
49. Sa1496 - No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in DAA-Naïve Patients: An Integrated Resistance Analysis of the POLARIS-2 and POLARIS-3 Studies
50. 508 - Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.